LONDON–(BUSINESS WIRE)– #EyewearMarket–The Global Eyewear Market will grow by USD 57.69 bn during 2020-2024
Author: Business Wire
ProtoKinetix AAGP® Restores Vision in Blind Test Subjects
MARIETTA, Ohio–(BUSINESS WIRE)– #AAGP–ProtoKinetix AAGP® Restores Vision in Blind Test Subjects
Aviceda Therapeutics Appoints Biopharma and Business Veterans Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA to its Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics is a pre-clinical stage biotech company focused on the next generation of glycol-immune therapeutics utilizing the Glyco-Code technology to address the innate immune system and chronic non-resolvi…
Guide Dogs for the Blind Partners With Be My Eyes to Give Real-Time Video Assistance to Alumni via Innovative App
SAN RAFAEL, Calif.–(BUSINESS WIRE)– #BeMyEyesApp–Guide Dogs for the Blind partnered with Be My Eyes, an innovative app, that provides real-time video assistance to people who are visually impaired.
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glauco…
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disease…
Naomi Kelman Appointed to National Vision’s Board of Directors
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, today announced the appointment of Naomi Kelman, former CEO and president at W…
STAAR Surgical Announces Completion of Patient Enrollment in EVO Implantable Lens US Clinical Trial
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, is today announcing that patient enrollment for the primary st…
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,…
KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)—- $KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors,…
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences, a clinical-stage biopharmaceutical company developing a novel class of tumor targeted therapies for initial application in primary tumors such as choroidal melanoma, today announced the dosing of the…
Nouvelles données sur Enspryng (Satralizumab) de Chugai sur le risque et la sévérité des rechutes dans le trouble du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé la présentation de nouvelles données sur Enspryng® (nom générique : satralizumab [recombinaison génétique]) dans la réduction de la sévérité des rechutes dans le traitemen…
中外製藥的Enspryng (Satralizumab)影響泛視神經脊髓炎(NMOSD)復發風險和嚴重程度的新資料
東京–(BUSINESS WIRE)–(美國商業資訊)—中外製藥株式會社(TOKYO:4519)發表Enspryng®（學名：satralizumab [基因重組])降低中樞神經系統罕見疾病泛視神經脊髓炎(NMOSD)復發嚴重程度的新資料。上述資料於第8屆ACTRIMS-ECTRIMS聯合會議MS Virtual 2020上呈報，同時呈報有關Enspryng降低NMOSD復發風險持久效應的長期有效性和安全性資料及其效益風險特性。Enspryng是中外製藥研製的一種pH依賴性結合型人類化抗IL-6…
Samenvatting: Nieuwe gegevens van Chugai’s Enspryng (Satralizumab) over risico en ernst van terugval bij neuromyelitis optica spectrum disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde de presentatie aan van nieuwe Enspryng® (generieke naam: satralizumab [genetische recombinatie]) gegevens over het verminderen van de ernst van terugval bij de behandeling v…
Resumen: Nuevos datos de Enspryng (satralizumab) de Chugai sobre el riesgo y la gravedad de la recaída en el trastorno del espectro óptico de la neuromielitis (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKIO:4519) ha anunciado la presentación de nuevos datos de Enspryng® (nombre genérico: satralizumab [recombinación genética]) sobre la reducción de la gravedad de las recaídas en el tratamiento …
Desk Lamps With Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Sold at Costco, to Support Children’s Learning and Protection From Myopia
ANSAN, South Korea–(BUSINESS WIRE)– #BetterSleep–Desk lamps with Seoul Semiconductor SunLike Series natural spectrum LEDs, which help improve learning and protect from myopia, sales at Costco.
Neue Daten von Chugais Enspryng (Satralizumab) zu Risiko und Schweregrad eines Rückfalls bei Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kündigten die Präsentation neuer Enspryng®-Daten (generischer Name: Satralizumab [genetische Rekombination]) zur Verringerung der Schwere des Rückfalls bei der Behandlung von Neuromy…
Optikos Receives ISO 13485:2016 Medical Device Certification
WAKEFIELD, Mass.–(BUSINESS WIRE)– #contractmanufacturing–Optikos Corporation receives ISO 13485:2016 certification for the design, manufacture, and distribution of medical devices.
Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will host a ke…
Ashvattha Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in oncology, ocular, and inflammatory diseases, today announced that Jeffre…